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Sphingolipids exhibit extreme functional and chemical diversity
that is in part determined by their hydrophobic moiety, ceramide.
In mammals, the fatty acyl chain length variation of ceramides is
determined by six (dihydro)ceramide synthase (CerS) isoforms.
Previously, we and others showed that mutations in the major
neuron-specific CerS1, which synthesizes 18-carbon fatty acyl (C18)
ceramide, cause elevation of long-chain base (LCB) substrates and
decrease in C18 ceramide and derivatives in the brain, leading to
neurodegeneration in mice and myoclonus epilepsy with dementia
in humans. Whether LCB elevation or C18 ceramide reduction leads
to neurodegeneration is unclear. Here, we ectopically expressed
CerS2, a nonneuronal CerS producing C22–C24 ceramides, in neu-
rons of Cers1-deficient mice. Surprisingly, the Cers1 mutant pa-
thology was almost completely suppressed. Because CerS2
cannot replenish C18 ceramide, the rescue is likely a result of LCB
reduction. Consistent with this hypothesis, we found that only
LCBs, the substrates common for all of the CerS isoforms, but
not ceramides and complex sphingolipids, were restored to the
wild-type levels in the Cers2-rescued Cers1 mutant mouse brains.
Furthermore, LCBs induced neurite fragmentation in cultured neu-
rons at concentrations corresponding to the elevated levels in the
CerS1-deficient brain. The strong association of LCB levels with
neuronal survival both in vivo and in vitro suggests high-level
accumulation of LCBs is a possible underlying cause of the CerS1
deficiency-induced neuronal death.
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Sphingolipids carry out essential functions in eukaryotes (1).The hydrophobic moiety of sphingolipids, called ceramide, is
a fatty acylated long-chain base (LCB). LCBs can differ in their
degree of saturation (e.g., sphingosine vs. dihydrosphingosine/
sphinganine) or hydroxylation (e.g., sphingosine vs. phytosphingo-
sine) (2). LCBs and their phosphorylated derivatives are potent
signaling molecules (3). Moreover, accumulation of aberrant
deoxy-LCBs has recently been linked to hereditary sensory and
autonomic neuropathy type 1 and taxane-induced peripheral
neuropathy (4–6). Very high concentrations (100 μM) of regular
LCBs are also toxic to cultured neurons (7, 8). In addition, in-
toxication with fumonisin B1, a fungal ceramide synthase inhibitor
causing elevation of LCBs and reduction of ceramides, leads to
neural tube and neurological defects in humans and cattle (9).
However, whether accumulation of regular LCBs in vivo or LCB
treatment at physiologically relevant concentrations in vitro causes
neuron death or damage has not been thoroughly investigated.
The fatty acyl chain of ceramide can also vary in chain lengths,
saturation, and hydroxylation (2). Emerging evidence suggests
specific functions for different ceramide species. For instance,
ceramide with a C18 fatty acyl chain (C18 ceramide) has been
suggested to cause apoptosis in certain cancer cells, whereas
ceramide with a C16 fatty acyl chain (C16 ceramide) has been
considered prosurvival (10–12). The ceramide profile changes in
aging and neurodegenerative brains, but whether these alterations
contribute to the pathogenesis, and the biological significance of
ceramide diversity, are unknown (13).
(Dihydro)ceramide synthase (CerS1–CerS6) isoforms synthe-
size (dihydro)ceramide, using a shared LCB substrate, dihy-
drosphingosine or sphingosine (14). Each CerS uses a selection
of different, sometimes overlapping fatty acyl-CoA substrates,
and therefore produces a spectrum of ceramide species (15).
CerS1–CerS6 also display different expression patterns. For in-
stance, CerS1 produces C18 ceramide and is neuron-specific in
the brain, whereas CerS2 synthesizes C22 and C24 ceramides but
is mainly present in oligodendrocytes in the brain (16, 17).
A Cers1 polymorphism resulting in increased CerS1 activity
has been shown to correlate with enhanced longevity in humans
(18). Conversely, a mutation reducing CerS1 activity has been
associated with myoclonus epilepsy and dementia (19). In mice,
we and others have shown that loss of CerS1 activity triggers
early-onset cerebellar ataxia and cerebellar Purkinje cell de-
generation, with ubiquitin-positive lipofuscin-like deposits in the
brain (20, 21). Brain sphingolipid profiling revealed profound
changes, including a >50% decrease of C18 ceramide species
and, consequently, significant reduction of the total ceramide
level and drastic increase of dihydrosphingosine and sphingosine,
the LCB substrates shared by all CerS isoforms (20). However, it
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was not clear which of these changes (e.g., the increase in LCBs
or the decrease in C18 ceramide) was causal to the pathologies.
Also, it is not known whether ceramide species with different fatty
acyl chains are interchangeable, nor do we know whether dif-
ferent ceramide synthases can be functionally interchangeable.
To answer these questions, we set out to uncouple the production
of C18 ceramide with accumulation of LCBs by modulating
ceramide biosynthesis in Cers1-deficient mutant brains through
ectopic expression of the nonneuronal CerS2 that produces C22
and C24 instead of C18 ceramides in the neurons (16, 17).
Results
Generation of Neuron-Specific Cers2 Transgenic Mice. The Cers2
coding sequence was placed downstream of the rat neuron-specific
enolase 2 promoter (Eno2) (22). A transgenic mouse line, C57BL/
6J-Tg(Eno2-Cers2)7Pjn (hereafter referred to as Tg-Cers2), was
selected to cross with the toppler (FVB/N-Cers1to) mutant, which
bears a loss-of-function mutation of Cers1 (20). Whole brains of
F2 mice were collected for analyses. Real-time quantitative PCR
showed that Cers2 transcript levels were increased by two- to
threefold in Cers1+/+;Tg-Cers2 or Cers1to/to;Tg-Cers2 brains com-
pared with wild-type (Cers1+/+) or Cers1to/to mice (Fig. 1A), but the
Cers1 mRNA level was unaffected (Fig. 1B). Consistently, CerS2
protein levels were also increased by expression of the transgene
(Fig. 1C). In agreement with previous reports (17), in wild-type
mice, CerS2 is only expressed in oligodendrocytes [adenomatous
polyposis coli (APC)-positive] (Fig. 1 D–F), but not neurons such
as Purkinje cells (IP3R1-positive) and granule neurons in the
cerebellum (Fig. 1 G–I). In contrast, in Tg-Cers2 cerebella, strong
CerS2 staining was found in Purkinje cells in addition to oligo-
dendrocytes (Fig. 1 J–L). Cerebellar granule neurons also display
clear increase of CerS2 protein expression (Fig. 1 J–L). Similarly,
hippocampal neurons in wild-type mice displayed extremely low
CerS2 protein level (Fig. S1 A–C), whereas Tg-Cers2 hippocampal
neurons showed much increased CerS2 expression (Fig. S1 D–F).
In addition, CerS2 level was low in wild-type cerebral cortical
neurons (Fig. S1 G–I), but was strongly elevated in the Tg-Cers2
cortical neurons, except those in layers II and IIIa (Fig. S1 J–L).
Thus, our results confirmed the pan-neuronal expression of CerS2
in mice carrying the Tg-Cers2 transgene.
Neuron-Specific Cers2 Expression Suppresses Cers1Mutant Phenotype.
Cers1to/to mutants display early-onset ataxia (20), whereas
Cers1to/to;Tg-CerS2 mice did not show cerebellar ataxia, even at 1 y
of age. Moreover, none of the mice carrying the Tg-Cers2 trans-
gene alone in the Cers1 wild-type background (Cers1+/+;Tg-Cers2)
exhibited any locomotor defects. Thus, ectopic neuronal expression
of Cers2 is sufficient to correct the behavioral defects caused by
Cers1 deficiency in mice neurons.
Purkinje cell loss in Cers1to/to mutants started around 3 wk after
birth (20) and was quite obvious by 10 mo, as shown by immu-
nohistochemistry with antibodies to Purkinje cell marker calbindin
D-28 (Fig. 2 A and B). Tg-Cers2 alone did not cause visible changes
in Purkinje cells in Cers1 wild-type mice. Importantly, in Cers1to/to;
Tg-Cers2 cerebella, Purkinje cells were intact (Fig. 2C), and Cers2
transgene indeed suppressed Purkinje cell loss (Fig. 2 D–F). This
was also confirmed by cresyl violet staining (Fig. 2 G–I). Thus,
ectopic expression of CerS2 was sufficient to compensate for the
loss of functional CerS1 that is critical for Purkinje cell survival.
Previously, we had shown that ubiquitin-positive lipofuscin-like
deposits were common in several brain regions, such as the hip-
pocampus (20). Compared with the wild-type (Fig. 3 A–C), Cers1to/to
mouse hippocampus harbored many ubiquitin-positive deposits
(Fig. 3 D–F). In contrast, Cers1to/to;Tg-Cers2mice had significantly
fewer deposits in the hippocampus (Fig. 2 G–I). Therefore, neu-
ronal expression of Cers2 greatly suppressed accumulation of
ubiquitin-positive, lipofuscin-like deposits caused by Cers1 deficiency.
Neuronal Expression of CerS2 Modifies Brain Sphingolipid Profile. To
find out how the Cers2 transgene rescued the Cers1 mutant phe-
notype, we examined brain sphingolipid profiles. CerSes produce
(dihydro)ceramides by using LCBs (e.g., dihydrosphingosine or
sphingosine) and fatty acyl-CoA as substrates (Fig. 4A). Previously,
we have shown that in the brain, the loss-of-function Cers1to/to
mutation caused reduction of C18 ceramide (CerS1 product), and
as a result, reduction of total ceramide levels, and led to accu-
mulation of the LCB substrates (20). To elucidate how ectopic
Cers2 overexpression in Cers1to/to neurons alters sphingolipid me-
tabolism, we compared sphingolipid profiles of Cers1to/to;Tg-Cers2
mouse brains with those of the wild-type and Cers1to/to brains.
Fig. 1. Cerebellar neuronal expression of CerS2 from a transgene. (A and B)
Real-time PCR results showing changes of the expression of Cers2 (A) and Cers1
(B) transcripts in brains of 4-wk-old Cers1 wild-type (+/+), Cers1 wild-type with
the neuron-specific Cers2 transgene (+/+ Tg), homozygous Cers1 toppler mutant
(to/to), and Cers1 toppler mutant with the Cers2 transgene (to/to Tg). Values are
mean ± SD (three mouse samples, four technical replicates for each sample).
**P ≤ 0.01 (one-way ANOVA, multiple comparisons). (C) A representative
Western blot analysis showing the CerS2 protein level in the brain. Genotypes of
mice are as described in A and B. The blot was redeveloped with an antibody
against α-tubulin as a loading control. (D–l) Immunohistochemistry of brain
sections from 4-wk-old wild-type (D–I, +/+) and Tg-CerS2 (J–L, +/+ Tg) mice,
using antibodies against CerS2 (D, G, and J), APC (E), and IP3R (H and K).
Merged images are also shown (F, I, and L). Purkinje cells and oligodendrocytes
are marked with large and small arrowheads, respectively. Cerebellar cell layers
are labeled as GCL (granule cell layer), WM (white matter), ML (molecular layer),
or PCL (Purkinje cell layer). (Scale bar, 50 μm.)
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To our surprise, the total amount of ceramide in Cers1to/to;
Tg-Cers2 brains remained very similar to the Cers1to/to brain
ceramide level, which was much lower than the ceramide level in
wild-type brains (Fig. 4B). As expected, on the basis of the CerS2
substrate specificity for C22–C24 fatty acyl-CoA, C18:0 and C18:1
ceramide levels were not affected by Cers2 transgene expression
(Fig. 4C). Previously, we observed that levels of C16, C22, and C24
ceramide species were increased in Cers1-deficient mouse brains,
likely because of the surplus of LCBs available to other neuronal
CerSes that use C16, C22, and C24 fatty acyl-CoA (20) or because of
ceramidases capable of reverse activity (i.e., producing ceramides
from LCBs and fatty acids) (23, 24). In this study, surprisingly, C22
and C24 ceramide species were not further elevated by transgenic
expression of CerS2. Instead, the level of C16, C22, and C24
ceramide species were decreased to near wild-type levels in the
Cers1to/to;Tg-Cers2 brains (Fig. 4C). Thus, similar to in Cers1to/to
brains, the total amount of ceramide and the C18 ceramide level in
particular were still low in Cers1to/to;Tg-Cers2 mouse brains and
were not compensated by the increase of C22 and C24 cer-
amide species.
Next, we examined the levels of sphingomyelin, hexosylcer-
amides, and the very low abundance lactosylceramides. We have
shown previously that sphingomyelin species with C18 ceramide
were decreased in Cers1-deficient brains, whereas those with C16
species tended to increase relative to levels in wild-type brains in
parallel to the changes seen in ceramides (20). We found that
transgenic expression of Cers2 did not change sphingomyelin
species with different ceramide chains or the total amount of
sphingomyelin in Cers1to/to brains (Fig. S2A, Inset). However, the
Cers2 transgene expression did result in significant elevation of
C22 and C24:1 hexosylceramides and the total amount of hex-
osylceramide (Fig. S2B, Inset). The rest of the hexosylceramide
species were not significantly increased. Similarly, C22 and C24
lactosylceramide species displayed significant increase in Cers1to/to;
Tg-Cers2 brains, although the total lactosylceramide levels
were not significantly different in wild-type, Cers1to/to, and Cers1to/to;
Tg-Cers2 brains (Fig. S2C, Inset). Our results indicate that neuro-
nal Cers2 expression results in increased production of the simple
C22 or C24 glycosphingolipids, presumably because the very long
chain ceramides produced by CerS2 were channeled into glyco-
sphingolipids instead of sphingomyelin. Taken together, our data
showed that profiles of sphingomyelin, hexosylceramides, and
lactosylceramides were not reverted to wild-type levels and were
also different from those of the Cers1to/to brains, indicating that
changes of these lipids are not likely to be causal to neuronal loss
in Cers1 mutant mice.
GM1 ganglioside has been reported to be lower in Cers1 knock-
out mouse brain (21). We observed a similar trend in the Cers1to/to
mutant brain (Fig. S3 A and B). However, the reduction is minor
and ectopic expression of CerS2 in neurons did not significantly
change GM1 ganglioside compared with the wild-type or Cers1to/to
mutant level. We did not observe significant changes of other gan-
glioside species such as GD1a and GT1b (Fig. S3 C and D) in the
Cers1to/to mutant brains or Cers1to/to;Tg-Cers2 brains.
Neuronal Expression of CerS2 in the CerS1 Mutant Restored Free LCBs
to Wild-Type Levels. Previously, we showed that the Cers1to/to
mutation also caused a drastic increase of CerS substrates, free
LCBs (20). To determine whether the suppression of Cers1
mutant pathology by Tg-Cers2 might be associated with changes
in free LCB levels, we quantified free LCBs in Cers1to/to;Tg-Cers2
mouse brains. Indeed, neuronal expression of Cers2 in Cers1to/to
brains effectively reduced the levels of free dihydrosphingosine
and sphingosine, as well as their phosphorylated metabolites, to
wild-type levels (Fig. 5 A–D). We also examined 1-deoxy LCBs,
including 1-deoxysphinganine (also known as spisulosine or
ES-285 in chemotherapy), which has been shown to cause central
nervous system neurotoxicity and peripheral neuropathy in hu-
mans (4, 5, 25–27). 1-Deoxysphinganine built up in Cers1to/to
mouse brains, but the accumulation was suppressed by the Cers2
transgene expression (Fig. 5E). We did not observe significant
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Fig. 2. Neuronal expression of Cers2 suppresses Purkinje cell death caused
by Cers1-deficiency. (A–F) Calbindin D-28K immunohistochemistry of cere-
bella from 10-mo-old wild-type (A), Cers1to/to (B), and Cers1to/to;Tg-Cers2 (C)
mice. Lobule X of each cerebellum was shown in detail (D–F). Sections are
close to midline. [Scale bars, 1 mm (A–C) or 100 μm (D–F).] (G–I) Cresyl Violet
staining of cerebella from 10-mo-old wild-type (G), Cers1to/to (H), and Cers1to/to;
Tg-Cers2 (I) mice. Detail in Lobule X was shown. Arrows point to Purkinje cells.
(Scale bar, 100 μm.)
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Fig. 3. Neuronal expression of Cers2 suppresses accumulation of ubiquitin-
positive deposits caused by Cers1 deficiency. Immunohistochemistry showing
ubiquitin (A, D, and G), NeuN (B, E, and H) staining, or merge images (C, F,
and I) of hippocampal CA3 region of 15-mo-old wild-type (A–C, +/+), Cers1to/to
(D–F, to/to), and Cers1to/to;Tg-Cers2 (G–I, to/to Tg) mice. Two cells still harboring
ubiquitin-positive deposits in the to/to Tg-Cers2 hippocampus are marked with
arrowheads (G and I). Note the reduction of NeuN staining in the to/to hip-
pocampus. (Scale bars, 50 μm.)
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differences of 1-deoxysphingosine in brains of different geno-
types (Fig. 5F). Next, we examined the levels of total LCBs (e.g.,
free LCBs plus the LCB moieties in ceramides and complex
sphingolipids) to assess the overall effect of CerS1 deficiency and
ectopic CerS2 expression on LCB metabolism. Our data showed
that, unlike free LCBs, the total LCB level was not significantly
affected by CerS1 deficiency and ectopic CerS2 expression (Fig.
5G). Consistently, the SPT activity was similar in wild-type, Cers1to/to,
and Cers1to/to;Tg-CerS2 mouse brains (Fig. 5H). Thus, the over-
all LCB metabolism was not significantly perturbed by CerS1
deficiency or CerS2 overexpression. Moreover, these results
demonstrate that, unlike profiles of total ceramide, neutral
glycosphingolipids, and complex sphingolipids, levels of free
LCBs were fully reverted to wild-type levels by expression of the
Cers2 transgene in Cers1-deficient neurons. Thus, the strong as-
sociation of reduced free LCB levels with neuronal survival sug-
gests that accumulation of free LCBs is most likely the cause of
the CerS1-deficient neuropathology.
LCBs Cause Neurite Fragmentation in Vitro. We then assessed neu-
rotoxicity of LCBs to cultured primary neurons. To mimic the
in vivo levels of LCBs, we calculated the concentrations of LCBs
based on the mass spectrometry data (Fig. 5) and on the as-
sumption that protein weight is about 10% of brain tissue wet
weight, as reported previously (28). Our calculation indicated that
tissue concentrations of dihydrosphingosine and 1-deoxysphinganine,
two LCBs that showed most drastic increase in Cers1to/to brains, are
15 and 0.15 μM, respectively. We used these concentrations in the
treatment of primary neurons. Similar to untreated neurons (Fig. 6
A–D), dihydrosphingosine at 1 μM, the concentration found in wild-
type brain tissue, did not cause significant damage (Fig. 6 E–H).
However, fragmentation of neurites and apoptosis were clearly vis-
ible at 15 μM, the concentration corresponding to the one in the
Cers1to/to brains (Fig. 6 I–L). The 0.15-μM deoxysphinganine con-
centration, corresponding to the level in the CerS1-deficient brains,
led to rather minor neurite damage or apoptosis, as visible by par-
tially fragmented β tubulin III labeling or TUNEL assay, respectively
(Fig. 6 M–P). Thus, our results confirmed that above physiological
level, free LCBs, especially high-level dihydrosphingosine, are highly
toxic to neurons.
Discussion
We have generated a mouse model (Cers1to/to;Tg-Cers2) that
uncoupled the changes of the shared CerS substrates, free LCBs,
with the changes of the CerS products, ceramides, by ectopically
expressing CerS2 in neurons of CerS1 mutant mice. The overall
neurological phenotype of this model, unlike the CerS1 mutant
that displays neurodegeneration, was nearly indistinguishable from
that of the wild-type mice. To find out the sphingolipids causing
neurodegeneration in CerS1 mutant brains and the mechanism of
suppression of the CerS1 mutant pathology by ectopic expression
of CerS2, we performed detailed sphingolipid profiling. Brain
ceramide and sphingomyelin showed significant differences in
wild-type and CerS1 mutant brains, but ectopic CerS2 expression
did not significantly change the total level or the fatty acyl chain
length profiles (Fig. 4 and Fig. S2A), strongly suggesting that
changes in ceramide and sphingomyelin levels are likely not the
cause of neurodegeneration in CerS1 mutant mice. Surprisingly,
expression of Tg-CerS2 in CerS1-deficient neurons did not lead
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Fig. 5. Sphingolipid metabolite profiles in the brain with neuronal expression
of Cers2. (A–E) Free LCB levels in the brain, including dihydrosphingosine
(dhSph; A), sphingosine (Sph, B), dihydrosphingosine-1-phosphate (dhS1P; C),
sphingosine-1-phosphate (S1P; D), 1-deoxy-sphinganine (DeoSa; E ), and
1-deoxy-sphingosine (DeoSph; F). (G) Total LCB levels, including free LCBs and
LCB moieties in brain sphingolipids. (H) SPT activity of brain microsomes using
20 μM C16-CoA substrate. Four mice (n = 4) of wild type (+/+) and three mice
(n = 3) of CerS1to/to or CerS1to/to;Tg-Cers2 were used. Values are mean ± SD.
*P ≤ 0.05; **P ≤ 0.01 (one-way ANOVA, multiple comparisons).
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Fig. 4. Ceremide profiles in the brain with neuronal expression of Cers2.
(A) Simplified schematic diagram of the sphingolipid biosynthesis pathway in
mammal, showing key metabolites such as dihydrosphingosine (dhSph),
dihydroceramide (dhCer), ceramide (Cer), sphingosine (Sph), and sphingosine-
1-phosphate (S1P), as well as a few enzymes involved including ceramide
synthase 1–6 (CerS1–CerS6) and ceramidases (CDases). (B and C ) Brain
ceramide levels of 40-d-old Cers1 wild-type (+/+, unfilled bars), homozygous
Cers1to/to mutant (to/to, filled bars), and Cers1to/to;Tg-Cers2 (to/to Tg, hatched
bars) mice. Profiles of total amounts of ceramides (B) and individual ceramides
species (C) are shown. Three mice (n = 3) of each genotype were used. Values
are mean ± SD. *P ≤ 0.05; **P ≤ 0.01 (one-way ANOVA, multiple comparisons).
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to an increase of CerS2 products, C22 and C24 ceramides. It is
possible that, unlike C18 ceramide, which abundantly exists as free
form in the brain, most C22 and C24 ceramides are preferably in-
corporated into complex sphingolipids. This hypothesis is sup-
ported by the observation that levels of C22 hexosylceramides and
several very long chain lactosylceramide species are significantly
increased in brains of Cers1to/to;Tg-Cers2 mice compared with the
wild-type or the Cers1to/to mice (Fig. S2 B and C).
Pan-neuronal knockout of the gene encoding glucosylceramide
synthase, the first enzyme in neutral and complex glycosphingolipid
biosynthesis, during neural development has led to early Purkinje
cell degeneration (29), but the pathogenic mechanism is not clear.
It should be noted that the nestin-cre used to drive deletion of the
gene is expressed in all neuronal and glia precursors, and the effect
of this knockout to sphingolipid metabolism was not fully examined
(i.e., whether simple sphingolipids and metabolites were affected is
unclear). In contrast to the glucosylceramide synthase knockout, in
our mouse models, however, the total level of hexosylceramides
was not significantly altered, suggesting that in our model, reduction
and replenishment of glucosylceramide is not the cause of Purkinje
cell degeneration and suppression of degeneration, respectively.
Particular hexosylceramides, namely, those derived from the C18
ceramide, were reduced in the CerS1-deficient mouse, but not
replenished after expression of CerS2. Thus, it is unlikely that re-
duction of C18 hexosylceramide led to Purkinje cell degeneration. It
should be noted that our data do not rule out the general impor-
tance of glucosylceramide for neural development. Similar to hex-
osylceramide, total lactosylceramide level was not changed by the
CerS1 mutation. Furthermore, the profile of lactosylceramide
species was not affected either. Therefore, lactosylceramide is
likely irrelevant to CerS1 pathology.
Gangliosides, complex glycosphingolipids derived from gluco-
sylceramide, have been found to be important for brain function.
However, our data did not show significant changes in the levels of
individual gangliosides, except GM1 gangliosides (Fig. S3), in
contrast to the work of Ginkel et al., who reported that ganglio-
sides were significantly reduced in CerS1 knockout brains (21).
Although the model studied by Ginkel et al. is similar, it is not
identical to the genetic model used in our studies; we used a CerS1
point mutant with impaired C18 ceramide synthase activity, but
similar expression level as the wild-type (20). The differences in
the two genetic models likely account for the discrepancies in the
observed levels of the ganglioside classes. Moreover, relevant
ganglioside-deficient mouse models do not recapitulate the Pur-
kinje cell loss phenotype observed in CerS1-mutant mice (30).
Although GM1-deficient mice show Wallerian degeneration and
mice lacking all gangliosides display white matter vacuolization in
the cerebellum, neither of these mice is known to have cerebellar
Purkinje cell degeneration (31, 32). Therefore, it is unlikely that
changes in ganglioside levels contributed to Purkinje cell de-
generation. Most recently, an alkaline ceramidase 3 knockout
mouse has shown elevation of ceramide, which was suggested to
be linked to Purkinje cell degeneration (33). However, this mouse
also showed elevation of LCBs, and the study did not clarify which
of the elevated sphingolipids, ceramide or LCBs, was neurotoxic.
In our model, the uncoupling of changes in the levels of shared
substrates (LCBs) from changes in the levels of the products
(ceramides with different fatty acid chain-length) strongly suggests
that elevation of LCBs is the primary cause of the neuropathology
in Cers1-deficient mice. Our treatments of cultured neurons using
LCBs (dihydrosphingosine and 1-deoxysphinganine) at concentra-
tions similar to the in vivo concentrations in Cers1to/to mouse brains
showed that only dihydrosphingosine was highly toxic (Fig. 6 G–I),
further suggesting that elevation of dihydrosphingosine is likely a
major cause of neurotoxicity resulting from CerS1 deficiency.
Methods
Genetic Constructs, Mice, and Antibodies. Primer sequences are listed in Table
S1. The mouse Cers2 ORF was amplified from C57BL6/J brain cDNA, using
primers LZO33 and LZO34, and inserted into the HindIII site of pNSE-Ex4 (20).
Pronuclear injection was performed on fertilized C57BL/6J oocytes, as reported
(20). Transgenic founders were genotyped using two sets of primers, LZO92
and LZO93 and LZO94 and LZO95. Two established transgenic lines, C57BL/6J-
Tg(Eno-Cers2)7Pjn and C57BL/6J-Tg(Eno-Cers2)45Pjn, were selected to cross
with the toppler (FVB/N-Cers1to) mutants. Genotyping of the topplermutation
was performed as described (20). The data obtained from the Tg(Eno-Cers2)7
line was used in this report, as the two lines have identical effects. Procedures
involving mice were approved by The Jackson Laboratory’s institutional animal
care and use committee according to national and international guidelines.
Primary antibodies were obtained and used as specified: rabbit polyclonal
anti-CerS2 (Sigma, cat no. HPA027262; 1:1,000 dilution for Western blot, 1:500
for immunohistochemistry), rat monoclonal antibody against α-tubulin (Santa
Cruz, cat no. sc-575; 1:1,000), rabbit antibody against Calbindin D-28 (Swant
CB38; 1:1,000), mouse monoclonal antibody against IP3R1 (NeuroMab, clone
L24-18; 1:200) (34), mouse monoclonal antibody against APC (EMD Millipore,
cat no. OP80; 1:200) (35), and mouse monoclonal antibody against neuron-
specific nuclear protein (NeuN; EMD Millipore, cat no. MAB377; 1:500). Mouse
anti–β-tubulin III antibody was purchased from Millipore (Clone TU-20, 1:500
dilution). Peroxidase conjugated secondary antibodies (Cell Signaling) were used
for Western blot, as suggested by the manufacturer. For immunohistochemistry,
Alexa fluor-conjugated secondary antibodies (Life Technologies; 1:200) were
used for fluorescent detection, and biotin-conjugated anti-rabbit secondary
antibody (Sigma B-7264; 1:100), in combination with peroxidase conjugated
ExtrAvidin (Sigma E-2886; 1:100), was used for colorimetric detection.
Quantitative Real-Time RT-PCR. Brain total RNA was extracted using TRIzol
reagent and used for cDNA synthesis with RetroScript cDNA synthesis kit (Life
Technologies). Real-time PCR was conducted using iTaq Supermix on a CFX96
Real-Time PCR System (Bio-Rad). Threemice of each genotype were used, and
four technical replicates were performed for each RNA sample. A Cers2 cDNA
Fig. 6. Toxicity of LCBs to cultured neurons. (A–L). Dihydrosphingosine
(dhSph) treatment of cortical neurons. Cortical neurons from E18 embryos
were untreated (A–D), or treated with 1 μM (E–H) or 15 μM (I–L) dhSph. (M–P)
Deoxysphinganine (DeoSa) treatment of cortical neurons. Neurons were
treated with 0.15 μMDeoSa. An area is enlarged in the Inset in P to show axon
fragmentation at its early stage (arrowheads). The rationale for using these
dhSph and deoSa concentrations was explained in detail in the Results. Neu-
rons, after fixation, were incubated with an antibody against neuron-specific
class III β-tubulin (A, E, I, andM; Tuj1), and then subjected to TUNEL assay (B, F,
J, and N) and counterstained with DAPI (C, G, K, and O). Merged images were
shown (D, H, L, and P). (Scale bar, 20 μm.)
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fragment was amplified with oligonucleotides LZO178 and LZO179. Gapdh, as
an internal control, was amplified using primers LZO184 and LZO185. Primers
LZO174 and LZO175 were used to amplify a Cers1 cDNA target fragment.
Quantitation of gene expression was calculated using ΔΔCt method, as de-
scribed (36). Relative abundances of Cers2 and Cers1 transcripts were nor-
malized to the amount of Gapdh.
Immunoblotting. Protein was extracted from mouse brains with RIPA buffer
(10 V of tissue weight) with protease inhibitor mixture III (EMD Millipore).
Protein samples were incubated with loading dye containing 3.3 M urea and
10 mM DTT to fully denature CerS2 before Western analysis.
Histology and Immunohistochemistry. Histology and immunohistochemistry
were conducted as described (20). Mice were perfused intracardiacally with
either 4% (wt/vol) paraformaldehyde (for CerS2, APC, and IP3R1 immuno-
staining) or 1:3 (vol/vol) acetic acid/methanol (for ubiquitin and NeuN
staining). Fluorescent images were acquired using identical parameters with
a Leica SP5 confocal microscope. For colorimetric detection of Calbindin D-28,
mice were perfused with Bouin’s fixative.
Lipid Extraction and Analyses of Sphingolipids. Lipid extraction and analyses of
sphingolipids including free LCBs, except gangliosides, were conducted es-
sentially as described (6, 20). Total LCBs were analyzed as previously described
(37). Mouse brain microsome preparation and SPT assay were conducted
as described (38). Extraction and analysis of gangliosides are described in
SI Methods.
Neuron Culture and Treatment. Primary cortical neurons were derived from E18
wild-type C57BL/6J mouse embryos as described (39). Dihydrosphingosine,
sphingosine, and deoxysphinganine were purchased from Avanti Polar Lipids
and used at specified concentrations.
Statistical Analysis. Statistical analysis for the real-time RT-PCR, sphingolipid
profiles (except gangliosides), and SPT activity were performed by ordinary
one-way ANOVA (Graphpad Prism 5). Adjusted P values (Tukey correction,
95% confidence interval) of multiple comparisons between any two of the
three groups were used. Statistical analysis for gangliosides was performed
using Sigma Plot.
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